This filing is routine and has no immediate trading implications. Monitor future equity grant disclosures to assess actual dilution. The plan amendment provides management with flexibility to issue stock-based compensation, which is standard for a development-stage biotech. No change to the company's cash position or operational outlook.
Price Chart
Executive Summary
Imunon, Inc. filed an 8-K reporting the results of its 2026 Annual Meeting held on June 16, 2026. Stockholders approved an amendment to the 2018 Stock Incentive Plan, increasing the aggregate share reserve by 1,000,000 shares to a total of 1,265,004 shares. The filing also covers the election of Class I directors, ratification of the independent auditor, and advisory approval of executive compensation. This is a routine post-meeting governance filing with no financial results or material operational updates.
Key Facts
- Stockholders approved an amendment to the 2018 Stock Incentive Plan, increasing the share reserve by 1,000,000 shares to 1,265,004 shares.
- Class I directors Frederick J. Fritz and Christine A. Pellizzari were elected with approximately 90% of votes cast in favor.
- WithumSmith+Brown, PC was ratified as independent auditor for FY2026 with 1,715,881 votes for, 81,399 against.
- Advisory say-on-pay for 2025 compensation was approved with 580,096 for, 115,666 against.
- Total shares outstanding as of record date: 3,983,342; quorum of 1,808,666 shares represented at the meeting.
Financial Impact
No financial figures reported. The plan amendment authorizes up to 1,265,004 shares for future equity awards, representing potential dilution of approximately 25% of current outstanding shares if fully granted.
Risk Factors
- Potential dilution from future equity awards under the expanded plan.
- Micro-cap biotech with $8M market cap faces high cash burn and financing risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-028937 |
| Document: form8-k.htm | 0001493152-26-028937 |
| Document: 0001493152-26-028937-index-headers.html | 0001493152-26-028937 |
| Document: 0001493152-26-028937-index.html | 0001493152-26-028937 |
| Document: 0001493152-26-028937.txt | 0001493152-26-028937 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | S-1 | $1.22 | awaiting T+5 | — | $0.9377 (+23.14%) |
Oct 27, 2026 today | 8-K | $1.25 | awaiting T+5 | — | $0.9377 (−24.98%) |
Oct 21, 2026 6d ago | 8-K | $1.19 | awaiting T+5 | — | $0.9377 (−21.20%) |
Sep 29, 2026 28d ago | 8-K | $1.34 $1.12 | ▲ +16.10% | ▲ +18.05% | $0.9377 (+29.76%) |
Aug 11, 2026 10w ago | 8-K | $1.61 $1.58 | ▼ −1.86% | ▼ −1.42% | $0.9377 (−41.76%) |
Aug 11, 2026 11w ago | 8-K | $1.61 $1.58 | ▼ −1.86% | ▼ −1.46% | $0.9377 (−41.76%) |
Jun 30, 2026 16w ago | 8-K | $1.88 $1.95 | ▲ +3.72% | ▲ +3.46% | $0.9377 (−50.12%) |
Jun 16, 2026 18w ago | 8-K | $1.86 $1.73 | ▼ −6.99% | ▼ −5.95% | $0.9377 (−49.59%) |
Jun 4, 2026 20w ago | 8-K | $2.10 $2.03 | ▲ +3.33% | ▲ +0.78% | $0.9377 (+55.35%) |
May 12, 2026 24w ago | 8-K | $2.70 $2.26 | ▼ −16.30% | ▼ −16.37% | $0.9377 (−65.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers